Abstract: The present invention relates to methods, treatment regimens, uses, kits and therapies for prevention of graft rejection in solid organ transplantation, particularly solid organ xenotransplantation, by administering an anti-CD40 antibody or a combination of an anti-CD40 antibody and an anti-C5 antibody.

Abstract: The invention provides double knockout transgenic pigs (GT/CMAH-KO pigs) lacking expression of any functional ?GAL and CMAH. Double knockout GT/CMAH-KO transgenic organs, tissues and cells are also provided. Methods of making and using the GT/CMAH-KO pigs and tissue are also provided.

Abstract: The invention provides double knockout transgenic pigs (GT/CMAH-KO pigs) lacking expression of any functional ?GAL and CMAH. Double knockout GT/CMAH-KO transgenic organs, tissues and cells are also provided. Methods of making and using the GT/CMAH-KO pigs and tissue are also provided.

Abstract: The invention provides double knockout transgenic pigs (GT/CMAH-KO pigs) lacking expression of any functional ?GAL and CMAH. Double knockout GT/CMAH-KO transgenic organs, tissues and cells are also provided. Methods of making and using the GT/CMAH-KO pigs and tissue are also provided.

Abstract: In human-human transplants, the organ recipient's serum is tested against a broad array of HLA (human leukocyte antigens) alleles. The current clinical assay almost performs a virtual crossmatch which allows elimination of incompatible donor organs in advance, but the current assay presents fragments of HLA polypeptides that are not normally visible to antibodies. As a result, the assay yields false positives. Further the current clinical assay is optimized for human to human transplant, not swine to human transplant. Some HLA antibodies also bind swine leukocyte antigens (SLA). Rather than using beads to present antigens, the compositions and methods provide cellular presentation of potential antigens. The application provides a modified human C1R cell line with significantly reduced antigenicity to human sera. Multiple cell lines, each expressing a different SLA, were created. The modified C1R line may express HLAs or other potential antigens of interest.

Abstract: The application provides methods of improving a rejection related symptom, reducing premature separation and methods of producing a compound of interest with an altered epitope profile are provided. Transgenic pigs with a disrupted gene or genes, and porcine organs, tissues, and cells therefrom are provided.

Abstract: The invention provides double knockout transgenic pigs (GT/CMAH-KO pigs) lacking expression of any functional ?GAL and CMAH. Double knockout GT/CMAH-KO transgenic organs, tissues and cells are also provided. Methods of making and using the GT/CMAH-KO pigs and tissue are also provided.

Abstract: The invention provides double knockout transgenic pigs (GT/CMAH-KO pigs) lacking expression of any functional aGAL and CMAH. Double knockout GT/CMAH-KO transgenic organs, tissues and cells are also provided. Methods of making and using the GT/CMAH-KO pigs and tissue are also provided.

Abstract: The application provides methods of improving a rejection related symptom, reducing premature separation and methods of producing a compound of interest with an altered epitope profile are provided. Knockout pigs with a disrupted gene or genes, and porcine organs, tissues, and cells therefrom are provided.

Abstract: The application provides methods of improving a medication related side effect in a human after transplant of transgenic organs, tissues or cells from transgenic pigs with a disrupted cellular transport gene or genes, and porcine organs, tissues, and cells therefrom are provided.

Abstract: The application provides methods of modulating platelet uptake by liver sinusoidal endothelial cells and of modulating thrombocytopenia. Transgenic pigs modified to bind fewer platelets are provided.

Abstract: The invention provides double knockout transgenic pigs (GT/CMAH-KO pigs) lacking expression of any functional aGAL and CMAH. Double knockout GT/CMAH-KO transgenic organs, tissues and cells are also provided. Methods of making and using the GT/CMAH-KO pigs and tissue are also provided.

Abstract: The application provides methods of modulating platelet uptake by liver sinusoidal endothelial cells and of modulating thrombocytopenia. Transgenic pigs modified to bind fewer platelets are provided.

Abstract: The invention provides double knockout transgenic pigs (GT/CMAH-KO pigs) lacking expression of any functional ?GAL and CMAH. Double knockout GT/CMAH-KO transgenic organs, tissues and cells are also provided. Methods of making and using the GT/CMAH-KO pigs and tissue are also provided.

Abstract: The application provides methods of modulating platelet uptake by liver sinusoidal endothelial cells and of modulating thrombocytopenia. Transgenic pigs modified to bind fewer platelets are provided.